|
Anti-PD-1 monoclonal antibody Clinical Trials
12 actively recruiting trials across 4 locations
▼ -1 trial since August 2026
Also known as: Anti-PD-1, Anti-PD-1 antibody, Camrelizumab Injection, Opdivo, PD-1 inhibitor +4 more
Pipeline
Phase 1: 1Phase 2: 4Phase 1/2: 6
Top Sponsors
- Ze-yang Ding, MD1
- University of Wisconsin, Madison1
- The First Affiliated Hospital of Soochow University1
- Second Affiliated Hospital, Zhejiang University, School of Medicine1
- LigaChem Biosciences, Inc.1
Indications
- Cancer12
- Solid Tumor2
- Liver Disease1
- Non-castrate Prostate Cancer1
- Oligometastatic Prostate Cancer (OMPC)1
Other8 trials
Phase 2
Birmingham, Alabama1 trial
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
University of Alabama at Birmingham
Phase 1/2
Scottsdale, Arizona1 trial
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
HonorHealth Research Institute
Phase 1/2
Los Angeles, California1 trial
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Cedars Sinai Medical Center
Phase 1/2
Madison, Wisconsin1 trial
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin - Madison
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.